What is the SUVN-502 Study?

The purpose of the SUVN-502 Study is to see whether an investigational medication – known as SUVN-502 – has an effect on the symptoms of Alzheimer’s disease when given along with the standard treatments, donepezil and memantine.

What is the investigational medication being tested?

Serotonin is one of the substances in the brain that plays a key role in the control of mood, behavior, and aggression. In Alzheimer’s disease, the brain has altered serotonin activity. SUVN-502 differs from other treatments for Alzheimer’s disease by working on a different chemical messaging pathway. SUVN-502 blocks a type of receptor (proteins on the surface of a cell or inside the cell that receive a particular type of substance and can only bind with that particular substance) for serotonin called the serotonin receptor subtype 6 (5-HT6 receptor). This affects serotonin action in the brain.

How will I know if I am eligible for this clinical research study?

If you are interested in taking part in the SUVN-502 study, answer a few questions to see if you qualify, and if you qualify, select the study center nearest to you, and provide your contact information. The study center will call, discuss the SUVN-502 study with you in more detail. The study staff will ask you some additional medical questions to see whether you are right for the study and the study is right for you. Then the study center will schedule you for an appointment.

Who sponsors clinical trials?

Clinical trials are sponsored, or funded, by a variety of organizations, medical institutions, foundations, voluntary groups, and pharmaceutical companies, or individuals such as physicians, in addition to federal agencies such as the National Institutes of Health (NIH), the Department of Defense (DOD), and the Department of Veteran’s Affairs (VA). Trials can take place in a variety of locations, such as hospitals, universities, doctors’ offices, or community clinics.

Do I need to ask my regular doctor before I can participate in this clinical research study?

No. However, you should tell your usual doctor that you are thinking of participating in this clinical research study. Your doctor may wish to contact the study doctor (with your permission) to request additional information.

Will I have to switch doctors?

Most clinical research studies provide short-term study-related treatment for a specific condition. Clinical research studies do not provide extended or comprehensive primary health care. Your family doctor may wish to work with the study team to best determine which treatments or medications are most appropriate for your care. At the end of the study, your care will return, in full, to your regular doctor.

How will I be compensated for my participation in this study?

You will not receive payment for taking part in this study. However, the investigational medications and all study-related care will be provided to you without charge. Expenses associated with taking part in this study, for instance travel to/from the study center, may be reimbursed. Please refer to the Informed Consent Form for further details.

Where are the study centers?

The study sites are all located in the United States.

Who will have access to my name and the information collected during participation?

Your personally identifiable information (for example: name, address) will not be accessible to anyone who is not directly associated with this clinical research study, except with your permission or as required by law.

Any information that is gained from this clinical research study may be used for publishing results. However, this information will only be combined with other participant data and cannot be used to identify any given participant.

The sponsor of this clinical research study will not have access to any personally identifiable information submitted through this website.

Share this Study

If you know someone (family member or friend) who is considering new treatment options for Alzheimer's disease care, they may be interested in the SUVN-502 study.

Share Study